drugset
drugset / Trial / NCT02443090

Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

NCT02443090 ↗

Phase 2 Unknown 160 enrolled NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the safety and efficacy of fispemifene in men with secondary hypogonadism and sexual side effects.

Timeline

Start
2015-05
Primary completion
2015-10
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fispemifene Small molecule 450 mg Oral

Indications

erectile dysfunction hypogonadism sexual disorder